Liraglutide Switches Immune Cells From Inflammatory to Protective Mode in Obese Patients | Research

The takeaway

Three months of liraglutide treatment shifted macrophages in obese patients from inflammatory (M1) to anti-inflammatory (M2) type, potentially explaining how GLP-1 drugs protect the heart beyond weight loss.

M1 → M2 shift
Liraglutide switched macrophages in obese patients from inflammatory to anti-inflammatory phenotype after 3 months — potentially explaining GLP-1 drugs' cardiovascular protection

What the researchers found

Three months of liraglutide treatment in obese patients shifted their macrophages from the inflammatory M1 type toward the anti-inflammatory M2 type. This phenotype switch was accompanied by reduced TNFα release (a key inflammatory cytokine) and decreased oxidative stress markers (reactive oxygen species and malondialdehyde).

This is one of the first in vivo human studies to show that GLP-1 analogs directly alter immune cell behavior — not just in a lab dish but in actual patients. The shift toward M2 macrophages could help explain why GLP-1 drugs reduce cardiovascular events: M1 macrophages drive atherosclerotic plaque formation and instability, while M2 macrophages promote tissue repair.

Why it matters

Large clinical trials have shown that GLP-1 drugs like liraglutide and semaglutide significantly reduce heart attacks and strokes, but the mechanism goes beyond simple weight loss and blood sugar control. This pilot study provides a potential explanation: GLP-1 drugs may calm the immune cells (macrophages) that drive atherosclerosis. Since macrophages are central to plaque formation, instability, and rupture, switching them from inflammatory to anti-inflammatory could directly protect arteries — a 'bonus' cardiovascular effect on top of metabolic benefits.

The numbers in context

3-month liraglutide treatment · Macrophage shift from M1 → M2 phenotype · Reduced TNFα release · Decreased ROS and malondialdehyde · Markers assessed: iNOS, arginase 1, mannose receptors, IL-1β, TNFα

How the study worked

Pilot clinical study in patients with obesity treated with subcutaneous liraglutide for 3 months. Macrophages were obtained from patients before and after treatment. Researchers assessed phenotypic markers (inducible nitric oxide synthase, arginase 1, mannose receptors), proinflammatory cytokine release (IL-1β, TNFα), and oxidative stress markers (reactive oxygen species, malondialdehyde).

Who was studied

Patients with obesity treated with liraglutide for 3 months (pilot study, exact sample size not specified in abstract)

What this study cannot tell us

This is a pilot study with a small, unspecified sample size. There was no placebo or control group — the before/after design means confounders like weight loss itself could drive the macrophage changes. The study didn't determine whether the macrophage changes translate to reduced atherosclerotic events. IL-1β changes were not specifically noted in the results. Published in a lower-impact journal (Metabolites).

How to read the evidence

This is a pilot study without a control group, representing preliminary evidence. The in vivo human data is valuable, but the small size and before-after design limit conclusions about causation. Larger controlled studies are needed.

When this study was published

Published in 2024. This is recent research providing mechanistic insight into a rapidly evolving field of GLP-1 cardiovascular immunology.

The bigger picture

The cardiovascular benefits of GLP-1 drugs are well-established but incompletely understood. Weight loss and blood sugar control don't fully account for the 20-26% reductions in major cardiovascular events seen in large trials. This study adds a mechanistic piece to the puzzle: GLP-1 drugs may directly reprogram the immune cells that drive atherosclerosis. If confirmed in larger studies, this could influence how clinicians think about prescribing GLP-1 drugs — not just for metabolic benefit but specifically for cardiovascular immune modulation.

Questions still open

Is the macrophage phenotype shift caused by liraglutide directly, or is it secondary to weight loss and metabolic improvement?
Do newer GLP-1 drugs like semaglutide produce even greater macrophage reprogramming effects?
Could macrophage phenotype be used as a biomarker to predict which patients will get the most cardiovascular benefit from GLP-1 therapy?

Common questions

What are M1 and M2 macrophages?

Macrophages are immune cells that can switch between different modes. M1 macrophages are 'inflammatory warriors' — they produce chemicals that fight infection but also drive plaque buildup in arteries. M2 macrophages are 'repair specialists' — they calm inflammation and help heal tissue. In obesity, macrophages tend to be stuck in M1 mode, which promotes chronic inflammation and atherosclerosis.

Does this mean liraglutide works as an anti-inflammatory drug?

In a way, yes. While liraglutide is primarily prescribed for diabetes and weight management, this study suggests it has significant anti-inflammatory effects on the immune system. The shift from M1 to M2 macrophages and reduced TNFα and oxidative stress markers all point to an anti-inflammatory action that may contribute to the cardiovascular benefits seen in large clinical trials.

Read the original research

Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers-A Pilot Study.

Metabolites, 14(10)

View on PubMed ↗Publisher’s paper ↗

Citation

Bułdak, Łukasz; Bołdys, Aleksandra; Skudrzyk, Estera; Machnik, Grzegorz; Okopień, Bogusław. (2024). Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers-A Pilot Study.. Metabolites, 14(10). https://doi.org/10.3390/metabo14100554